Ortho Pharmaceutical Corporation

Johnson Matthey Inc.

Merck + Co., Inc.

The General Hospital Corporation

Howard F Solomon

Scott K Larsen

Gary James Bridger

Alan J Fischman

Robert H Rubin

John D Higgins, Iii

H William Strauss

Robert L Suddith

Daniel J Kroon

Raymond E Gibson

H Donald Burns

Michelle L Tomsho

Michael Bornstein

Claudia K Derian

Diane C Corbo

Pedro E Hernandez

N Adeyinka Williams

Anthony J Fuccello

Mary Jean Link

Nancy J Brenner

A lyophilized imaging agent formulation and methods for making same are disclosed, such formulations comprise a targeting molecule such as antibody or chemotactic peptide, a linker such as diethylenetriaminepentaacetic acid (DTPA) or succinimidyl 6-hydrazinium nicotinate hydrochloride (SHNH), drying protectant such as mannitol, maltose or tricine, and excipient such as polysorbate 80, in citrate buffer. The formulations of the invention are lyophilized and may be stored stably for extended periods of time. Following reconstitution with diluent, the formulations are administered to a subject for scintigraphic imaging or therapeutic use. Also contemplated is a kit comprising a two-vial system wherein a first vial comprises a lyophilized formulation of imaging agent in the form of a lyophilized cake, and a second vial comprises a pharmaceutically acceptable carrier or diluent.

Lyophilized imaging agent formulation comprising a chemotactic peptide

The invention relates to a method of detecting a site of infection or inflammation, and a method for treating such infection or inflammation, in an individual by administering to the individual a diagnostically or therapeutically effective amount of detectably labeled, therapeutic, or therapeutically-conjugated, chemotactic peptide that accumulates substantially at the infected or inflamed site, said chemotactic peptide having the general structure

Labeled chemotactic peptides to image focal sites of infection or

Novel radiolabeled cholecystokinin-A (CCK-A) antagonists have been developed which, after intravenous injection, localize in the pancreas as a result of specific binding to CCK-A receptors. These tracers, when labeled with appropriate radiohalogens, are useful as commercial diagnostic imaging radiopharmaceuticals and radiotherapeutic drugs.

Gamma emitting, CCK-A antagonists for pancreatic imaging

Growing community of inventors

New Hope, PA, United States of America

Howard F Solomon